Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AETHLON MEDICAL INCAEMD · Entity 8580 | Chief Scientific Officer | February 01, 2023 | February 02, 2023 |
| PARDES BIOSCIENCES, INC.PRDS · Entity 110063 | Chief Scientific Officer | February 01, 2022 | February 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AETHLON MEDICAL INC
Report date February 01, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2033-01-31 | Direct | 60,620 |
Reported balance
After 2023-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 60,620 · Balance 60,620 F1: 25% of the shares subject to the stock option shall vest and become exercisable on February 1, 2024, and the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option shall vest and become exercisable on February 1, 2024, and the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter.
PARDES BIOSCIENCES, INC.
Report date February 01, 2022 · Filed February 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2032-01-31 | Direct | 100,000 |
Reported balance
After 2022-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-01 · Grant · Acquired 100,000 · Balance 100,000 F1: This option shall vest in substantially equal monthly installments over four years from February 1, 2022, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in substantially equal monthly installments over four years from February 1, 2022, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 2, 2023 21:14 UTC | AETHLON MEDICAL INC AEMD · Entity 8580 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,620 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001209191-23-006200 · doc4.xml · derivative · entry 1 Arnold Lee D · CIK 0001613258 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,620 Underlying: Common Stock · 60,620 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest and become exercisable on February 1, 2024, and the remaining shares shall vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 19:04 UTC | PARDES BIOSCIENCES, INC. PRDS · Entity 110063 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0000899243-22-004214 · doc4.xml · derivative · entry 1 Arnold Lee D · CIK 0001613258 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: This option shall vest in substantially equal monthly installments over four years from February 1, 2022, subject to a continued service relationship. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2021 Stock Option and Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.